BPI-1178 Clinical Trials

2 actively recruiting trials

No change since May 2026

Also known as: BPI-1178 capsule

Pipeline

Phase 1: 1Phase 1/2: 1

Top Sponsors

National Cancer Center, China1
Beta Pharma (Suzhou) Co., Ltd.1

Indications

Cancer2
HR+/HER2- Breast Cancer1
Advanced Solid Tumor1
NSCLC1
Lung Cancer1

Other2 trials

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations

Phase 1

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.